BBIO NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

BridgeBio Pharma Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 84.02 USD
3.2% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 16.0% above the Trend Line and sits at 81.7% of its 52-week range. The latest completed week returned 3.2%, after a 19.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 61 out of 100
Latest Close 84.02 USD 24 Jul 2026
1W Return 3.2% latest completed week
4W Return 19.6% short-term follow-through
12W Return 22.5% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 8 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.2% Latest completed week; four-week move 19.6%. Indicator stack 48/90 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 51/100 conviction; expected move 10.7%. News sentiment 57/100 63 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 16.0% above the Trend Line and sits at 81.7% of its 52-week range. The latest completed week returned 3.2%, after a 19.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4012-week average 0.36

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.40Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers88 reversal markers

No recent accumulation markers. 8 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 19.6% over four weeks, 22.5% over 12 weeks, and 81.5% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W3.2%
4W19.6%
12W22.5%
26W7.9%
52W81.5%
Active trend streak1 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.90Latest activity-pressure read.
Pressure change299.1%Four-week change in activity pressure.
Leadership15.59Latest relative-leadership reading.
RS change488.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength69/100Blend of value, momentum, and quality. Underlying universe rank 32; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality57/100Profitability and accounting quality. Underlying universe rank 44; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth59/100Revenue and earnings growth. Underlying universe rank 42; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
28.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-2.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
93.8%
Gross profit retained from each unit of revenue.
Operating margin
-106.5%
Operating profit retained from revenue.
Free-cash-flow margin
-74.8%
Free cash flow generated from revenue.
Return on invested capital
-196.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
355.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.6%
Net share repurchases relative to market value.
Shareholder yield
0.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-4.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

BBIO shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.02, expected move of 10.7%, and Sharemaestro trend signal active.

Conviction51/100
Expected move10.7%
Put/call volume0.02
Pressure93
Speculation12
Volatility76
Trend agreement4
Open options detail
Insider activity7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 63 relevant articles.

22 positive · 38 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move10.7%Nearest-chain priced movement where available.
52-week drawdown-10.1%Distance below the 52-week high.
13-week volatility5.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+11.3%Week of 10 Jul.
Worst week-11.9%Week of 6 Feb.
Latest week+3.2%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains5
Flat weeks0
Modest losses8
Sharp losses6
Recent vol5.3%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew5.1% / -3.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape57/100

Trend, activity pressure, participation, and risk combine to a 57/100 tape read.

 Indicator analysis23/100

Latest 12-week confirmation: trend 2/12, activity pressure 3/12, relative leadership 4/12.

Activity pressure 0.40; 8 reversal markers Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 34; Small Cap Core rank 49 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

BBIO shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.02, expected move of 10.7%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 10.7% Sentiment57/100

Weighted news tone is neutral across 63 relevant articles.

BridgeBio earnings on deck as company eyes four-product future Insiders7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.

 Research flow2 items

1 recent research articles and 1 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202684.02 USD3.2%72.41 USD43.00 USD0.9015.598.3MOn
17 Jul 202681.38 USD-5.3%72.14 USD42.68 USD0.7210.9913.0MOff
10 Jul 202685.89 USD11.3%71.97 USD42.38 USD0.2912.9734.6MOff
3 Jul 202677.19 USD9.9%71.61 USD41.95 USD-0.294.0212.9MOff
26 Jun 202670.24 USD6.0%71.50 USD41.56 USD-0.45-4.0239.0MOff
19 Jun 202666.27 USD-0.8%71.55 USD41.22 USD-0.67-13.2411.2MOff
12 Jun 202666.80 USD-1.2%71.62 USD40.90 USD-0.60-10.049.8MOff
5 Jun 202667.61 USD2.0%71.60 USD40.56 USD-0.58-6.5520.1MOff
29 May 202666.26 USD-4.1%71.41 USD40.23 USD-0.73-12.1710.7MOff
22 May 202669.12 USD4.5%71.29 USD39.90 USD-0.63-5.3112.6MOff
15 May 202666.13 USD-1.9%70.79 USD39.54 USD-0.57-7.7714.1MOff
8 May 202667.39 USD-1.7%70.42 USD39.21 USD-0.48-5.8114.9MOn
1 May 202668.56 USD-6.4%70.02 USD38.86 USD-0.441.5723.2MOn
24 Apr 202673.28 USD-4.5%69.50 USD38.51 USD-0.5310.7211.1MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.